As a proud sponsor of the 2026 BioInnovation Festival, Fund WA is here to back the next generation of world-class breakthroughs born right here in Western Australia. WA has always punched above its weight in science—we’ve produced a staggering share of Australia’s FDA-approved drugs and house some of the world’s most advanced research labs. Yet, for too long, local founders have hit a “funding gap” just as their ideas were ready to take flight. Fund WA was built to change that.

We are a Perth-based venture capital team focused on Seed to Series A investments. Our mission is personal: we provide the capital, mentorship, and networks that WA innovators need to scale globally without having to move their headquarters or their intellectual property; interstate or overseas. Led by people who have actually built and scaled businesses, we look for high-growth ventures solving the biggest challenges in health, med-tech, and biotech.

We’re interested in supporting those turning bold lab discoveries into market-ready realities. We look forward to connecting with you at the Festival. It’s a great opportunity to chat about the future of WA’s scientific excellence and how we might support your journey.

Website: www.fundwa.com.au

Curtin University is committed to practical, solutions-driven research in the life-sciences, across disciplines including healthcare, agriculture and biotechnology. The Curtin Medical Research Institute (Curtin MRI) showcases our commitment to impactful research and commercialisation. Curtin MRI researchers focus on age-related diseases, chronic conditions and precision medicine, working collaboratively with industry and government partners to translate discoveries into real-world applications. From developing new treatments for neurodegenerative diseases to advancing cancer diagnostics, Curtin MRI’s work is shaping the future of healthcare.

Our long-standing research capabilities across agriculture (notably supporting Australian crop growers to fight disease) and allied health further exemplify the breadth of Curtin’s approach to life sciences research and commercialisation.

Our Commercialisation team play a crucial role in transforming research outcomes into market-ready solutions. By fostering partnerships with industry leaders and entrepreneurs, the team ensures that life-changing discoveries reach those who need them most. Their expertise in intellectual property management, licensing and startup development supports the transition of medical innovations from lab to patient.

With world-class researchers, state-of-the-art facilities and a strong focus on translational research, Curtin is driving major advancements in life sciences.

Website: https://www.curtin.edu.au/ 

CSL (ASX:CSL; USOTC:CSLLY) is a leading global biopharma company with a dynamic portfolio of lifesaving medicines, including those that treat haemophilia and immune deficiencies, vaccines to prevent influenza, and therapies in iron deficiency, dialysis and nephrology. Since our start in 1916, we have been driven by our promise to save lives using the latest technologies. Today, CSL – including our three businesses, CSL Behring, CSL Seqirus and CSL Vifor – provides lifesaving products to patients in more than 100 countries and employs 29,000+ people. Our unique combination of commercial strength, R&D focus and operational excellence enables us to identify, develop and deliver innovations so our patients can live life to the fullest. For inspiring stories about the promise of biotechnology, visit CSL.com/Vita

For more information about CSL, visit CSL.com.

Edith Cowan University’s dedication to providing industry-relevant research and award-winning facilities fosters outside the box thinking and a culture that embraces creativity to tackle challenges and seize opportunities.

ECU’s world-class research delivers meaningful real-world impact and solutions to some of our greatest global challenges. ECU works closely with local communities and industry partners to ensure we are focused on the challenges that matter.

Our research partnerships are diverse and meaningful. From aged care providers to airports; the Department of Primary Industries and Regional Development to Rio Tinto; our research delivers relevant and impactful contributions to society. Whether its developing nature-based solutions and innovation for sustainability, or shaping the future of healthcare with genomics and precision health, ECU researchers together with industry partners are delivering the power to drive change.

With campuses in Joondalup, Mount Lawley and Bunbury, ECU is set to launch in the heart of Perth in late 2025, when ECU City opens its doors. This Perth city centred campus will be a place where technology, industry and creativity meet to deliver impactful research, and the creative thinkers, adaptive learners and global citizens who our world so desperately needs as the leaders of tomorrow.

Website: https://www.ecu.edu.au/

For 50 years, orthopaedic surgery has relied on mechanical bone-cutting tools that were the best technology available for their time. While advances in imaging, navigation and robotics have greatly improved planning and guidance, the underlying cutting method has remained largely unchanged. This has naturally placed boundaries around surgical accuracy, implant design and the ability to consistently preserve native bone and soft tissue. As demand for joint replacement grows, patient outcomes have begun to plateau and hospitals face increasing pressure on theatre capacity and waitlists. ArthroLase introduces a step change in joint replacement through HAiLO™, a robotic laser system that digitally sculpts bone with sub-millimetre precision. This transition – from mechanical cutting to intelligent digital shaping – opens the door to a new era of Faster, Better and Smarter surgery. Faster, by reducing operative time through high-speed laser shaping and streamlined digital workflows. Better, by preserving bone and soft tissue, improving implant fit and supporting more natural movement and recovery. Smarter, by lowering consumables, reducing variability and enabling advanced, bone-preserving implant designs. By expanding what is technically possible in bone preparation, ArthroLase builds on decades of orthopaedic progress and helps shape the next generation of surgical care.

Website: https://www.arthrolase.com/

The Fisheries Research and Development Corporation (FRDC) takes a leading role in planning and investing in research, development and extension (RD&E) activities that benefit Indigenous, aquaculture, commercial and recreational fishers, and the wider Australian community.

FRDC’s investments aim to balance shared national priorities and specific jurisdictional opportunities while also helping our partners develop innovative responses to specific issues. We are also responsible for ensuring that our RD&E assists with managing Australia’s fisheries, aquaculture and marine resources for their ongoing sustainability.

FRDC is a statutory corporation under the Primary Industries Research and Development Act 1989 (the PIRD Act) and is responsible to the Minister for Agriculture, Fisheries and Forestry.

We are pleased to demonstrate our commitment to innovation through FRDC’s sponsorship of the 2026 BioInnovation Festival.

Visit www.frdc.com.au for more information.

We strive to cultivate and preserve Western Australia’s agriculture, food industry, and aquatic resources while also building vibrant regional communities with flourishing economies.

The Perron Institute for Translational and Neurological Science, formerly the Western Australian Neuroscience Research Institute, is Western Australia’s longest established medical research institute and has facilities within the QEII Medical Centre and Murdoch University. It brings together world-class scientists who have made ground breaking discoveries, yet it also has specialist neurology clinics with leading neurologists. This is its unique strength. The Institute provides a pathway for translating research into positive health outcomes for the community. Its work helps those suffering from conditions such as stroke, Parkinson’s, multiple sclerosis, motor neurone, spinal cord injury and muscle disorders such as muscular dystrophy and myositis. The Perron Institute has formal affiliations with The University of Western Australia, Murdoch University, the WA Department of Health and Sir Charles Gairdner Hospital. The Institute also has well-established links with universities and hospitals worldwide.

Moderna is a leader in the creation of the field of mRNA medicine. Through the advancement of mRNA technology, Moderna is reimagining how medicines are made and transforming how we treat and prevent disease for everyone. By working at the intersection of science, technology and health for more than a decade, the company is developing a range of new medicines and vaccines. For more information about Moderna, please visit modernatx.com.au

Perth Biodesign provides educational training in healthcare innovation using the Stanford Biodesign methodology, which focuses on a prescriptive method of identifying unmet clinical needs, inventing solutions that address these needs and creating implementation strategies that fit within the complex healthcare landscape. 

In Perth Biodesign courses, we bring together multidisciplinary teams of people passionate about making a difference in healthcare and build the connection between industry, academia, health services, and specialised services providers to create a healthcare innovation opportunity. Perth Biodesign programs are experiential in nature, focusing on biomedical entrepreneurship, are designed for the Australian biomedical environment, and thrive on the support of the local ecosystem.

Website: https://www.perthbiodesign.au